| Asthma |
| Not yet recruiting | 3 | 60 | | | University of Otago, Lottery Grants Board NZ, Asthma and Respiratory Foundation of NZ | Exercise induced wheeze, Asthma | | | | |
| Not yet recruiting | 3 | 60 | | | Adelaide University, Department of Medicine, Adelaide University funds | Asthma | | | | |
| Not yet recruiting | 3 | 100 | | | Dr Stuart Armstrong, Dr Stuart Armstrong | Asthma | | | | |
| Not yet recruiting | 3 | 100 | | | Dr Stuart Armstrong, Dr Stuart Armstrong | Asthma | | | | |
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme |
|
|
| Not yet recruiting | 3 | 102 | Europe | , Inhalation powder, pre-dispensed, Bricanyl, Symbicort | Centre Hospitalier Intercommunal de Créteil, Astrazeneca | moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ACTRN12616000112460p: The Fine Particle Aerosols in Uncontrolled Asthma Study: Efficacy of small aerosol versus large aerosol budesonide in the treatment of uncontrolled asthma in adults. |
|
|
| Not yet recruiting | 3 | 120 | | | Woolcock Institute of Medical Research, NH&MRC | Asthma | | | | |
ACTRN12616000112460: The Fine Particle Aerosols in Uncontrolled Asthma Study: Efficacy of small aerosol versus large aerosol budesonide in the treatment of uncontrolled asthma in adults. |
|
|
| Not yet recruiting | 3 | 120 | | | Woolcock Institute of Medical Research, NH&MRC | Asthma | | | | |
ACTRN12623001339640: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist as maintenance and reliever therapy versus as prescribed maintenance with salbutamol as reliever therapy in children with moderate and severe asthma. |
|
|
| Not yet recruiting | 3 | 376 | | | The University of Auckland, Heath Research Council of New Zealand, Cure Kids | Asthma | | | | |
| Recruiting | 3 | 52 | | | Nguyen Van Toan, none | Asthma, Chronic obstructive pulmonary disease (COPD) | | | | |
| Recruiting | 3 | 64 | | | Hunter New England Area Health Service, NHMRC | Asthma | | | | |
| Active, not recruiting | 3 | 600 | | | Woolcock Institute of Medical Research, NHMRC, CRC for Asthma | Asthma | | | | |
ACTRN12622001217796: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma. |
|
|
| Recruiting | 3 | 400 | | | Medical Research Institute of New Zealand, AstraZeneca Ltd | Asthma | | | | |
ACTRN12623000670673: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist reliever therapy regimen in preschool children with mild asthma/recurrent wheeze. |
|
|
| Recruiting | 3 | 280 | | | The University of Auckland, Health Research Council of New Zealand, Cure Kids | Asthma. | | | | |
| Completed | 3 | 480 | | One vial of placebo, intramuscular injection, once a week for 12 weeks as one course of treatment ;One vial of M.vaccae, intramuscular injection, once a week for 12 weeks as one course of treatment | Shanghai ChangZheng Hospital; Anhui Longkema Biological Pharmaceutical Co., Ltd., Anhui Longkema Biological Pharmaceutical Co., Ltd. | Asthma | | | | |
NCT00986726: Effect of Temperature Controlled Laminar Airflow (TLA) on Rhinitis |
|
|
| Active, not recruiting | 3 | 14 | Europe | Protexo (Temperature controlled Laminar Airflow (TLA)), Protexo, Placebo TLA | Airsonett AB, Croel AB, Commitum AB | Asthma | 01/10 | 02/10 | | |
ChiCTR-TRC-10000765: Multicenter clinical study on light moderate asthma by aerosol inhalation of Mycobacterium Phlei |
|
|
| Completed | 3 | 300 | | Utilin 1.72UgX2+Saline 3ml, inhalation, once a day, 5 days/a course of treament.6days, one month, 3 months, 6 months,1 year after treament review the indicator respectively, and carry one intensive therapy, 3 days/one course of treatment. Use Ventolin if they need, inform the patients inhaled Ventolin twice per day with 2 spray while use Utilin at the beginning of 1-3 days. ;Seretide 50/100μg, do falling-rising ladder adjust ;As a negative control of group A apply saline 5ml,inhalation, once perday, 5 days/a course of treatment. At the beginning of 1-3days inform the patients inhaled Ventolin twice per day with 2 spray. Based on ethical objections, do 5days observation, If overcome non-effective results (mainly refer to no improvement in symptoms. review no reduces airway responsiveness) should combined the patients to group A or B;if overcome effective resullts, do the same way of group A, program the intensive ther | Department of Public Health of Guangxi Zhuang Autonomous Region; 1st Affiliate Hospital of Guangxi Medical University, Department of Public Health of Guangxi Zhuang Autonomous Region | Asthma | | | | |
| Completed | 3 | 450 | | one inhalation of Pulmicort Turbuhaler 200 ug/inhalation ;Oxis Turbuhaler 4.5 ug/inhalation with symptom-driving ;Symbicort Turbuhaler 160/4.5 ug/inhalation with symptom-driving | 1st Affiliated Hospital of SYSU; 2nd and 3rd Affiliated Hospital of SYSU, 1st Affiliated Hospital of SYSU | mild asthma | | | | |
2011-005553-31: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma. |
|
|
| Ongoing | 3 | 4036 | Europe | Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Inhalation powder, pre-dispensed, Relvar Ellipta | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2012-005678-76: SUBLINGUAL IMMUNOTHERAPY IN PEDIATRIC ASTHMA Immunoterapia sublinguale nell'asma pediatrico |
|
|
| Ongoing | 3 | 170 | Europe | Staloral 300 acari, Sublingual solution of HDM Allergen Extracts, Oral drops | ALLEGRIA onlus, AIFA | Allergic asthma to house dust mites Asma allergico agli acari della polvere, Allergic asthma Asma allergico, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ChiCTR-TRC-11001189: Clinical Research on the Treatment of Moderate Bronchial Asthma with Inhaled Inactivated-Mycobacterium Phlei |
|
|
| Completed | 3 | 60 | | The patients in group A were treated with inhaled inactivated-mycobacterium phlei F.U.36 Injection 1.72ug/mL*2 that adding 3mL normal saline, once a day for 7 days. one month, 3 months, 6 months after treament review the indicator respectively, and carry one intensive therapy, 3 days/one course of treatment. They can inhale Ventol as need to relieve symptoms. ;The patients in B group were treated with salmeterol xinafoate and fluticasone propionate powder for inhalation 50/100ug, twice daily for sustainable use. They can inhale Ventol as need to relieve symptoms. | Department of Public Health of Guangxi Zhuang Autonomous Region; 1st Affiliate Hospital of Guangxi Medical University, Department of Public Health of Guangxi Zhuang Autonomous Region | asthma | | | | |
VDAART, NCT00920621: Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma |
|
|
| Active, not recruiting | 3 | 876 | US | Vitamin D 3 cholecalciferol, vitamin D, vitamin D3, cholecalciferol, Vitamin D3 | Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 01/15 | 02/24 | | |
2014-004431-38: Efficacy and Safety of LAIS® in patients with allergic rhinoconjunctivitis to ragweed pollen Studio clinico su efficacia e sicurezza di LAIS® in pazienti con ricongiuntivite allergica al polline di ambrosia |
|
|
| Ongoing | 3 | 228 | Europe | Lais® Ragweed Maintenance Therapy, Sublingual tablet, LAIS® Ragweed | Lofarma S.p.A., Lofarma S.p.A | Patients with allergic rhinoconjunctivities to ragweed pollen with or without asthma Pazienti affetti da rinocongiuntivite allergica al polline di ambrosia con o senza asma, Patients with allergic rhinoconjunctivities to ragweed pollen with or without asthma Pazienti affetti da rinocongiuntivite allergica al polline di ambrosia con o senza asma, Body processes [G] - Immune system processes [G12] | | | | |
2004-000755-41: A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthma |
|
|
| Ongoing | 3 | 34 | Europe | Formoterol Fumarate, Foradil 12µg poudre pour inhalation, CHF 1531, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation | Chiesi Farmaceurtici S.p.A | Children Persistent Asthma | | | | |
2004-001065-18: Morning versus evening administration of 500µg Roflumilast once dailyfor 6 weeks in patients with asthma. |
|
|
| Ongoing | 3 | 60 | Europe | Roflumilast, | ALTANA Pharma AG | Asthma | | | | |
2005-000276-40: A RANDOMISED, OPEN TWO WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW SALBUTAMOL-HFA 134a FORMULATION GIVEN AS CUMULATIVE DOSES AND A REFERENCE SALBUTAMOL-HFA 134a FORMULATION IN ADULT ASTHMATIC PATIENTS |
|
|
| Ongoing | 3 | 30 | Europe | Respigen, Ventolin Evohaler, Respigen, Ventolin Evohaler, Respigen, Ventolin Evohaler | GENERICS [UK] Ltd. | Documented asthma for at least 6 months before screeningSubjects with a FEV1 of between 50-85% of the predicted normal value for age, height and gender after withholding short acting Beta2-agonists for at least 6 hours and long-acting Beta2-agonists for at least 24 hours. | | | | |
2005-003826-24: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALER AND TWO REFERENCE DRY POWDER FORMULATIONS IN ADULT ASTHMATIC PATIENTS |
|
|
| Ongoing | 3 | 32 | Europe | formoterol, MIAT HALER, Foradil Aerolizer, Oxis Turbohaler, Foradil Aerolizer, Oxis Turbohaler | Andi - Ventis | reversible mild asthma | | | | |
2005-005469-12: A Phase III, randomised, double-blind, double-dummy cross-over study to compare two dry powder inhaled formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, moderate asthma. |
|
|
| Ongoing | 3 | 30 | Europe | Budesonide Test DPI, Pulmicort Turbohaler 200, Test DPI, Reference DPI, Pulmicort Turbohaler 200, Pulmicort Turbohaler 200 | Neolab Limited | Stable, persistent, moderate asthma | | | | |
2005-004744-32: A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EXISTING SALMETEROL–CFC PRODUCT |
|
|
| Ongoing | 3 | 35 | Europe | salmeterol, Serevent, Serevent | Merck Generics UK Ltd. | asthma bronchiale | | | | |
2006-002337-20: Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhood |
|
|
| Ongoing | 3 | 60 | Europe | rhDNase (tradename: Pulmozyme), Pulmozyme, Pulmozyme | Erasmus Medical Centre Rotterdam | Asthma is a chronic inflammatory disorder in which many cells play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible individuals this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. These symptoms are usually associated with widespread but variable airflow limitation that is at least partly reversible either spontaneously or with treatment. | | | | |
2006-003795-35: Mannitol inhalations as a faster procedure for testing of airways hyperresponsiveness |
|
|
| Ongoing | 3 | 120 | Europe | Methacholine, Aridol, Aridol | University Medical Center Groningen | Detection of airway hyperresponsiveness in patients with asthma or COPD | | | | |
2006-003385-34: The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma. |
|
|
| Ongoing | 3 | 24 | Europe | tiotropium bromide, BA 679 BR, Spiriva, Spiriva | Boehringer Ingelheim Pharma GmbH & Co. KG | 24 patients with mild persistent asthma will participate in the study. All patients will be allergic to one or more airborne allergens, hyperresponsive to histamine (PC20 < 8 mg/ml) and have a normal lung function (FEV1 > 70% of predicted). | | | | |
2006-000602-23: A randomized double blind, placebo controlled study to evaluate the efficacy and security of immunotherapy with a depigmented and polymerized allergen extract of Dermatophagoides pteronyssinus in patients with asthma. |
|
|
| | 3 | 90 | Europe | DPSL Dpt, DEPIGOID D. pteronyssinus, DEPIGOID D. pteronyssinus | Laboratorios LETI S.L. | Mild to moderate asthma caused by sensitization againts dust mite Dermatophagoides Pteronyssinus. | | | | |
2007-006227-12: A randomised, placebo controlled study of nebulised magnesium in acute severe asthma in children |
|
|
| Ongoing | 3 | 500 | Europe | Magnesium sulphate solution, N/A, | Cardiff University | Acute severe asthma | | | | |
2009-014036-37: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of house dust mites of Dermatophagoides pteronyssinus in patients with rhinitis/rhinoconjunctivitis with or without allergic asthma bronchiale |
|
|
| | 3 | 144 | Europe | House dust mite allergoid (Dermatophagoides pteronyssinus), | Allergopharma Joachim Ganzer KG | Immunoglobulin E (IgE)-mediated allergic disease in adults and adolescents manifested by allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma bronchiale (Global Initiative for Asthma [GINA]) triggered by non eliminable house dust mite allergens. | | 06/10 | | |
2010-019589-10: A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents. |
|
|
| Ongoing | 3 | 62 | Europe | Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Fluticasone Furoate/GW642444 Inhalation Powder, Seretide Accuhaler, FlixotideTM AccuhalerTM, Seretide Accuhaler, FlixotideTM AccuhalerTM | GlaxoSmithKline Research & Development Ltd | Persistent Asthma in Adults and Adolescents. | | | | |
2010-024440-15: Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternata Ensayo clínico multicéntrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalúa la eficacia clínica y seguridad de la inmunoterapia con el alérgeno mayor purificado Alt a 1, en pacientes con rinoconjuntivitis alérgica con o sin asma leve o moderada, sensibilizados al hongo Alternaria alternata |
|
|
| Ongoing | 3 | 153 | Europe | Alt a 1, Alt a 1, | DIATER Laboratorio de Diagnostico y Aplicaciones Terapéuticas S.A., DIATER Laboratorio de Diagnostico y Aplicaciones Terapéuticas S.A. | Allergic rhinoconjunctivitis with or without associated mild or moderate asthma. Rinoconjuntivitis alérgica con o sin asma leve o moderada asociada. | | | | |
| Ongoing | 3 | 55 | Europe | Mepolizumab, SB240563, | GlaxoSmithKline Research and Development Limited, GlaxoSmithKline Research and Development Limited | Subjects with severe, refractory asthma and a history of eosinophilic inflammation. | | | | |
2013-005615-27: A Phase 3 study to evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with asthma that is not controlled. |
|
|
| Ongoing | 3 | 78 | Europe | Tralokinumab, CAT-354, | AstraZeneca AB, AstraZeneca AB | Asthma | | | | |
2015-004959-50: HELIOX-DRIVEN BETA2-AGONISTS NEBULIZATION FOR CHILDREN WITH MODERATE TO SEVERE ACUTE ASTHMA: A RANDOMIZED CONTROLLED TRIAL HELIOX COMO VEHÍCULO EN LA NEBULIZACIÓN DE BETA 2-AGONISTAS EN NIÑOS CON ASMA AGUDO MODERADO-SEVERO: ENSAYO CLÍNICO CONTROLADO ALEATORIZADO |
|
|
| Ongoing | 3 | 58 | Europe | Heliox (Helium 22% Oxygen 78%), Aire Sintético Medicinal, Medicinal gas, compressed, Aire Medicinal Sintético Carburos Metálicos, 22% v/v gas medicinal, comprimido | S.E. Carburos Metálicos S.A. grupo Air Products, S.E. Carburos Metálicos S.A. grupo Air Products | Moderate to severe exacerbations of asthma EXACERVACION DE ASMA AGUDO DE MODERADO A GRAVE, Moderate to severe exacerbations of asthma EXACERVACION DE ASMA AGUDO DE MODERADO A GRAVE, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma. |
|
|
| Ongoing | 3 | 675 | Europe | Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms | Medical Research Institute of New Zealand, Astra Zeneca | Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-000188-15: Phase III trial of specific immunotherapy with allergoid preparation of house dust mite in patients with allergic bronchial asthma and with allergic rhinitis or rhinoconjunctivitis |
|
|
| Ongoing | 3 | 444 | Europe, RoW | House dust mite allergoid (Dermatophagoides pteronyssinus), Suspension for injection | Allergopharma GmbH & Co. KG, Allergopharma GmbH & Co. KG | allergic bronchial asthma and allergic rhinitis or rhinoconjunctivitis, asthma with symptoms of rhinitis or rhinoconjunctivitis caused by house dust mite allergens, Body processes [G] - Immune system processes [G12] | | | | |
2014-002659-25: An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085 |
|
|
| Not yet recruiting | 3 | 10 | Europe | Reslizumab, CEP-38072, Concentrate for solution for infusion | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Treatment for patients with eosinophilic asthma, A particular form of asthma characterized by the presence of a high number in the lungs of a certain type of white blood cells, called eosinophils, which lead to airways inflammation and symptoms., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-001532-19: An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthma |
|
|
| Not yet recruiting | 3 | 1006 | Europe | Fluticasone Furoate/Umeclidinium/Vilanterol, (Seretide Accuhaler/DISKUS), Spiriva Respimat, GW685698/GSK573719/GW642444, R03AK06, Inhalation powder, pre-dispensed, Inhalation solution, Trelegy Ellipta, Seretide Accuhaler/Diskus, 250/50 mcg or 500/50mcg, Spiriva Respimat | GlaxoSmithKline Research & Development Ltd, GSK | Inadequately controlled asthma, Inadequately controlled asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-002596-18: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma Efficacia e sicurezza dell’immunoterapia sublinguale con compresse di Allergoide LAIS Birch per pazienti con rinocongiuntivite allergica indotta da polline d’albero in presenza o assenza di asma lieve controllato |
|
|
| Not yet recruiting | 3 | 110 | Europe | Loratadina, Tablet, Eye drops, suspension, Nasal spray, suspension, CLARITYN - 20 COMPRESSE 10 MG, LEVOSTAB - 0.05 % COLLIRIO, SOSPENSIONE 1 FLACONE 4 ML, PREDNISONE DOC GENERICI - "5 MG COMPRESSE" 10 COMPRESSE IN BLISTER PVC-PVDC/ALU, RINOCLENIL - 50 MCG SPRAY NASALE, SOSPENSIONE FLACONE DA 200 EROGAZIONI | LOFARMA S.P.A., Lofarma S.p.A. | Tree pollen-induced allergic rhinoconjunctivitis Rinocongiuntivite allergica indotta da polline degli alberi, Tree pollen-induced allergic rhinoconjunctivitis Rinocongiuntivite allergica indotta da polline degli alberi, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-002498-23: The Role of Benralizumab on airway Remodeling Assessed by HRCT in severe asthma (BREATH Study) Il ruolo del Benralizumab sul rimodellamento delle vie aeree nell'asma grave valutato tramite HRCT (Studio BREATH) |
|
|
| Not yet recruiting | 3 | 20 | Europe | FASENRA, [MEDI-563], Solution for injection | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Astrazeneca | SEVERE ASTHMA ASMA GRAVE, SEVERE ASTHMA ASMA GRAVE, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Mepolizumab 40mg or 100mg | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Asthma | 12/19 | 12/19 | | |
| Not yet recruiting | 3 | 18 | Europe | Fasenra, Solution for injection, Fasenra | Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside, AstraZeneca UK Limited | Severe Eosinophilic Asthma, Severe Eosinophilic Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004429-26: A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and salmeterol (ComboFS) twice daily and the reference product Seretide® Diskus® in patients with asthma |
|
|
| Not yet recruiting | 3 | 200 | Europe | ComboFS 250 mcg/25 mcg, ComboFS 125 mcg/25 mcg, Seretide® Diskus® 500/50 mcg/dose, Seretide® Diskus® 250/50 mcg/dose, Capsule, Inhalation powder, pre-dispensed, Seretide® Diskus® 500/50 mcg/dose, Seretide® Diskus® 250/50 mcg/dose | PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA, PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA | asthma, asthma, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR1800016644: Clinical study in treatment of asthma by acupoint sticking therapy based on Raman spectrum in monitoring of dermatitis degree |
|
|
| Not yet recruiting | 3 | 150 | | Placebo application ;Acupoint application | Jiangsu Province Hospital of Chinese Medicine; Jiangsu Province Hospital of Chinese Medicine, Key R & D Program (Social Development) of Jiangsu science and Technology Department | Asthma | | | | |
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium |
|
|
| Not yet recruiting | 3 | 28 | Europe | QMF149, QVM149, Inhalation powder | University Medical Center Groningen, Novartis Pharma AG | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003715-22: Efficacy and Safety Evaluation for the Treatment of asthma and allergic rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a gramíneas y ácaros de polvo. |
|
|
| Not yet recruiting | 3 | 140 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Suspension for injection | Inmunotek, S.L., Inmunotek, S.L. | Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen. Asma de leve a moderada y rinitis/rinoconjuntivitis alérgica (intermitente o persistente) debida a hipersensibilidad a ácaros de polvo (Dermatophagoides pteronyssinus y/o D. farinae) y polen de gramíneas., Grass and house dust mite allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a gramíneas y ácaros de polvo (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002811-25: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis sensitized to grass and olive pollen Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a gramíneas y olivo |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T517 (10.000-10.000), MG01-T517-(30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y olivo, Grasses and olive tree allergy Alergia frente a Gramíneas y Olivo, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002865-37: Efficacy and Safety Evaluation for the Treatment of Allergy Against Cupressaceae and grasses. Evaluación de la eficacia y seguridad del tratamiento de la alergia a gramíneas y cupresáceas |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T521 (10.000-10.000), MG01-T521 (30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y cupresáceas, Grasses and cupressacease allergy Alergia frente a Gramíneas y cupresáceas, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 3 | 346 | | SalmexTM (fluticasone propionate 250 g, salmeterol 50 g) + sullide simulator ;Seretide (fluticasone propionate 250 g, SalmexTM 50 g) +SalmexTM emulator | The First Affiliated Hospital Of Guangzhou Medical University; Jiangsu Simcere Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co. Ltd | Adult bronchial asthma | | | | |
ACTRN12620001010987: A proof-of-concept single group study of an anti-inflammatory reliever therapy stepwise approach to the pharmacological treatment of adult asthma. |
|
|
| Active, not recruiting | 3 | 100 | | | Medical Research Institute of New Zealand, Medical Research Institute of New Zealand, AstraZeneca Ltd | Asthma | | | | |
2018-003674-27: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI). |
|
|
| Not yet recruiting | 3 | 1000 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), Budesonide Pressurized Inhalation Suspension (BD MDI), PT027, PT007, PT008, Pressurised inhalation, suspension | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Symptomatic Asthma, Symptomatic Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ANASSA-PD, NCT04665895 / 2020-002977-84: A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma |
|
|
| Completed | 3 | 451 | Europe | Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals, FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK, FLOVENT, Placebo | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma | 08/21 | 02/22 | | |
2021-000149-42: A study to compare SYN008 and Xolair for the treatment of chronic urticaria not well controlled by antihistamines |
|
|
| Ongoing | 3 | 480 | Europe | Omalizumab, Xolair, SYN008, Solution for injection in pre-filled syringe, Solution for infusion in pre-filled syringe, Xolair 150 mg solution for injection in pre-filled syringe | Synermore Biologics Co., Ltd, Synermore Biologics Co., Ltd | Chronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps), Asthma, urticaria, Chronic rhinosinusitis, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Not yet recruiting | 3 | 350 | Europe | Beltavac® with polymerized extract from Dermatophagoides, Suspension for injection | Probelte Pharma S.L.U., NA | Allergic rhinitis/ rhinoconjuntivitis associated or not with asthma rinitis/rinoconjuntivitis alérgica asociada o no con asma, House dust mite allergy Alergia a los ácaros del polvo, Diseases [C] - Immune System Diseases [C20] | | | | |
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation |
|
|
| Terminated | 3 | 102 | Europe | Budesonide Formoterol Drug Combination, nebulisation of terbutaline | Centre Hospitalier Intercommunal Creteil, AstraZeneca | Asthma in Children | 09/21 | 06/23 | | |
2021-001449-11: Study with adult asthmatic patients to understand how asthma symptoms are perceived by comparing two inhalers. Studio con pazienti adulti asmatici per capire come vengono percepiti i sintomi dell'asma confrontando due inalatori. |
|
|
| Not yet recruiting | 3 | 75 | Europe | Beclometasone dipropionato e formoterolo fumarato, Beclometasone dipropionato e formoterolo fumarato diidrato, [CHF1535], Pressurised inhalation, solution, FOSTER - 100/6 MICROGRAMMI PER EROGAZIONE SOLUZIONE PRESSURIZZATA PER INALAZIONE | CHIESI FARMACEUTICI S.P.A., Chiesi Farmaceutici S.p.a. | Moderate to severe asthma Asma da moderata a grave, Moderate to severe asthma Asma da moderata a grave, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-000190-81: Tiotropium in preventing preschool asthma (TIPP) Tiotropium zur Vorbeugung von Asthma bei Vorschulkindern |
|
|
| Not yet recruiting | 3 | 204 | Europe | tiotropium bromide inhalation solution, Inhalation solution | Goethe-University Frankfurt, Federal Ministry for Education and Research (BMBF), Boehringer Ingelheim | Severe asthma exacerbations in partial and uncontrolled preschool asthma Schweres Asthma-Exazerbationen bei teil- und unkontrolliertem Asthma im Vorschulalter, Severe preschool asthma Schweres Asthma im Vorschulalter, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003673-10: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007 in asthma patients 4 years of age or older (MANDALA). |
|
|
| Not yet recruiting | 3 | 3100 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), PT027, PT007, Pressurised inhalation, suspension, Ventolin Evohaler® 100 micrograms | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Moderate to severe asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05299385: The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) |
|
|
| Recruiting | 3 | 100 | RoW | Conventional rehabilition treatment(e.g leaflet) educated by hospital, the conventional rehabilitation treatment, Digital treatment based on Respiratory Rehabilitation Software, Respiratory Rehabilitation Software | Lifesemantics Corp., Asan Medical Center, KangWon National University Hospital, SMG-SNU Boramae Medical Center | Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer, Lung Diseases, Pulmonary Rehabilitation, Respiratory Rehabilitation, Home Based Rehabilitation, Mobile Application, Rehabilitation | 03/22 | 06/22 | | |
NCT02124226: Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma |
|
|
| Not yet recruiting | 3 | 102 | NA | Methotrexate, Several brand names, Placebo, matched placebo | Universita degli Studi di Catania | Low Dose Methotrexate in Severe Chronic Asthma | 04/22 | 07/22 | | |
2022-000215-31: Value of nasal provocation test with aspirin in the diagnosis of AERD in patients with chronic sinusitis with nasal polyps |
|
|
| Ongoing | 3 | 236 | Europe | Powder for oral solution in sachet, Solution for injection, Aspegic 500 mg - Powder for oral solution, Mini-Plasco NaCl B.Braun - Solution for injection - 0,9% | UZ Leuven, The Research Foundation – Flanders (FWO) | Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic RhinoSinusitis with Nasal Polyps (CRSwNP), Patients with chronic rhinosinusitis with nasal polyps, suffering from Aspirin Induced Asthma (AIA), Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000615-31: Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patients or investigators will know what the patient it's being given. This clinical trial evaluates efficacy and safety of the immunotherapy with allergen “Cup a 1” (major protein in Cupressus arizónica) in patients with allergic rhinoconjunctivitis with or without asthma sensitized to Cupressaceae pollen Ensayo clínico en varios centros, donde los pacientes reciben en paralelo aleatoriamente el tratamiento o el placebo (control). Ni investigadores ni pacientes sabrán qué tratamiento están recibiendo. El ensayo clínico evalúa eficacia clínica y seguridad de la inmunoterapia con el alérgeno “cup a 1” (proteína mayoritaria de Cupressus arizónica), en pacientes con rinoconjuntivitis alérgica con o sin asma, sensibilizados al polen de las Cupresáceas |
|
|
| Not yet recruiting | 3 | 150 | Europe | Cup a 1 purified and isolated protein, Cup a 1 MOL, Solution for injection in vial | Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas | Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma Pacientes alérgicos al polen de las Cupresáceas con rinoconjuntivitis alérgica moderada o grave, con o sin asma controlado, Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma Pacientes alérgicos al polen de las Cupresáceas con rinoconjuntivitis alérgica moderada o grave, con o sin asma controlado, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-006691-17: A Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteriod Use in Adults with Oral Corticosteriod Dependent Asthma |
|
|
| Not yet recruiting | 3 | 207 | RoW | Tezepelumab via APFS, MEDI9929 anti-TSLP mAb (AMG157), Solution for injection in pre-filled syringe | AstraZeneca AB, AstraZeneca AB, Amgen | Severe Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-006681-21: Care path consisting of a systematic assessment of asthma patients using digital home monitoring resulting in a patient-centred treatment Zorgpad bestaande uit een systematische beoordeling van astma patiënten met behulp van digitale thuismonitoring wat resulteert in een patiëntgerichte behandeling |
|
|
| Not yet recruiting | 3 | 138 | Europe | Budesonide/formoterol (BF) Digihaler Digital System (DS), Inhalation powder, BF Spiromax | Franciscus Gasthuis & Vlietland, Teva Pharmaceuticals, DSW Transformatiegelden | Asthma Astma, Asthma: alternating airway narrowing and - inflammation Astma: wisselende luchtwegvernauwing en -ontsteking, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Ongoing | 3 | 90 | Europe | Tezepelumab, Solution for injection in pre-filled syringe | University Hospital of Montpellier, AstraZeneca | exacerbating asthma, Severe asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05813470: Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma |
|
|
| Completed | 3 | 256 | RoW | Omalizumab (CinnaGen), Zerafil®, Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland), Xolair® | Cinnagen | Allergic Asthma, Uncontrolled Moderate to Severe | 01/23 | 01/23 | | |
2022-002977-27: This study will evaluate and confirm that a new formulation of Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals is therapeutically equivalent to the marketed formulation Advair DISKUS® 100/50 mcg inhalation powder/GSK in patients with asthma Aυτή η μελέτη θα αξιολογήσει και τεκμηριώσει ότι ένα νέο σκευάσμα Προπιονικής Φλουτικαζόνης 100mcg και Σαλμετερόλης 50mcg/Respirent Pharmaceuticals κόνις για εισπνοή είναι θεραπευτικά ισοδύναμο του εγκεκριμένου σκευάσματος ADVAIR DISKUS® 100/50mcg κόνις για εισπνοή/GSK σε ασθενείς με άσθμα |
|
|
| Ongoing | 3 | 451 | Europe | Fluticasone propionate 100μg/salmeterol 50μg (as xinafoate) inhalation powder/Respirent, Inhalation powder, pre-dispensed, ADVAIR DISKUS® | Respirent Pharmaceuticals Co. Ltd, Respirent Pharmaceuticals Co. Ltd | Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation Το άσθμα είναι μια ετερογενής ασθένεια, που συνήθως χαρακτηρίζεται από χρόνια φλεγμονή των αεραγωγών. Ορίζεται από ιστορικό αναπνευστικών συμπτωμάτων όπως συριγμός, δυσκολία στην αναπνοή, σφίξιμο στο στήθος και βήχα που μεταβάλλονται στο χρόνο αλλά και σε ένταση, μαζί με μια μεταβλητή απόφραξη των αεραγωγών., Asthma is a chronic inflammatory disease of the airways that is complex and characterized by symptoms as airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. Το άσθμα είναι μια χρόνια φλεγμονώδης νόσος των αεραγωγών που είναι σύνθετη και χαρακτηρίζεται από συμπτώματα οπως απόφραξη της ροής του αέρα, βρογχική υπεραντιδραστικότητα και υποκείμενη φλεγμονή, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 3 | 695 | RoW | Benralizumab, Placebo | AstraZeneca | Asthma | 01/23 | 01/23 | | |
|
|
| Completed | 3 | 78 | Europe | Exploratory study on patient's perception of Asthma symptoms | Chiesi Farmaceutici S.p.A. | Asthma | 02/23 | 02/23 | | |
| Completed | 3 | 1460 | Europe, Canada, US, RoW | Sublingual allergy immunotherapy tablet, Acarizax, Odactra, Placebo, Placebo sublingual tablet | ALK-Abelló A/S | Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite | 04/23 | 04/23 | | |
2022-003004-33: Assess the efficacy, safety, & tolerability of oral dexpramipexole in severe eosinophilic asthma |
|
|
| Not yet recruiting | 3 | 1395 | Europe | Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet | Areteia Therapeutics, Inc., Areteia Therapeutics, Inc. | Severe Eosinophilic Asthma, Severe Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04191434: Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma |
|
|
| Recruiting | 3 | 134 | RoW | Flamboyant 125/12, Budesonide/formoterol 200/6, Flamboyant 125/12 Placebo, Budesonide/formoterol 200/6 placebo | EMS | Asthma | 05/23 | 10/23 | | |
2021-003014-39: Efficacy and Safety Evaluation for the Treatment of house dust mite induced allergic asthma and rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a ácaros de polvo doméstico. |
|
|
| Not yet recruiting | 3 | 400 | Europe | MM09 allergoid-mannan conjugates SC (3.000), MM09 allergoid-mannan conjugates SL (3.000), MM09 allergoid-mannan conjugates SL (9.000), Solution for injection, Sublingual spray, solution | Inmunotek, S.L., Inmunotek, S.L. | Etiological treatment of mild to moderate controlled intermittent or persistent allergic asthma and intermittent or persistent allergic rhinitis / rhinoconjunctivitis Tratamiento etiológico de asma alérgica intermitente o persistente controlada de leve a moderada y rinitis/rinoconjuntivitis alérgica intermitente o persistente, House dust mite induced allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a ácaros de polvo doméstico (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT02455687: Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial. |
|
|
| Recruiting | 3 | 240 | RoW | Hi-dose iv MgSO4, Nebulized budesonide, Pulmicort, Std-dose iv MgSO4, Nebulized normal saline | Hamad Medical Corporation | Bronchial Asthma | 12/24 | 01/25 | | |
ACTRN12620001091998: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist reliever therapy regimen in children with mild asthma |
|
|
| Active, not recruiting | 3 | 360 | | | Medical Research Institute of New Zealand, Health Research Council of New Zealand, Cure Kids | Asthma | | | | |
| Not yet recruiting | 3 | 750 | Europe | Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet | Areteia Therapeutics, Inc., Areteia Therapeutics, Inc. | Eosinophilic Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04191447: Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma |
|
|
| Recruiting | 3 | 134 | RoW | Flamboyant 200/12, Budesonide / Formoterol 400/12, Flamboyant 200/12 Placebo, Budesonide / Formoterol 400/12 Placebo | EMS | Asthma | 07/23 | 10/23 | | |
AERO-PD, NCT05664061: Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma |
|
|
| Recruiting | 3 | 451 | Europe | Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, Test (T), ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Refernce (R), Placebo | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma | 07/23 | 12/23 | | |
| Active, not recruiting | 3 | 450 | Europe | Grass pollen extract - Alutard Phleum pratense, ALK, immunotherapy | Aarhus University Hospital, University of Aarhus, University Hospital, Linkoeping | Allergic Rhinitis Due to Grass Pollen, Allergic Conjunctivitis of Both Eyes, Allergic Asthma | 08/23 | 12/23 | | |
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient |
|
|
| Completed | 3 | 1485 | US | Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg | Cipla Ltd. | Asthma | 08/23 | 08/23 | | |
NCT05850494: Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma |
|
|
| Completed | 3 | 52 | US | HFA MDI, Propellant in MDI, HFO MDI | AstraZeneca | Asthma | 08/23 | 08/23 | | |
NCT05280418: Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma |
|
|
| Recruiting | 3 | 30 | Canada | Tezepelumab, Placebo | McMaster University | Asthma | 09/24 | 12/24 | | |
2020-000455-12: A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis |
|
|
| Not yet recruiting | 3 | 440 | Europe, RoW | 5-grass mix SLIT-drops, Oral solution in single-dose container | ALK-Abelló A/S, ALK-Abelló A/S | Grass pollen-induced allergic rhinoconjunctivitis for two years or more with or without asthma, Grass pollen-induced allergic rhinoconjunctivitis, Diseases [C] - Immune System Diseases [C20] | | | | |
ACTRN12620000566932: Randomised clinical trial of interventions for the treatment of COVID-19 in the community setting. |
|
|
| Terminated | 3 | 250 | | | University of Sydney, NSW Ministry of Health | COVID-19 | | | | |
NCT04874714: Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis |
|
|
| Terminated | 3 | 18 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Placebo subcutaneous | Inmunotek S.L., BioClever 2005 S.L., NTS hub S.L | Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy | 10/23 | 10/23 | | |
NCT04891237: Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen |
|
|
| Recruiting | 3 | 180 | Europe | 10,000 MG01 + 10,000 T517, Grasses and olea 10,000, 30,000 MG01 + 10,000 T517, Grasses and olea, Placebo | Inmunotek S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 10/25 | 01/26 | | |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Active, not recruiting | 3 | 580 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
| Completed | 3 | 395 | Europe, Canada, US, RoW | GSK3511294 (Depemokimab), Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 11/23 | 11/23 | | |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) |
|
|
| Recruiting | 3 | 790 | Europe | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 08/24 | 09/25 | | |
NCT04898283: Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. |
|
|
| Recruiting | 3 | 180 | Europe | 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521, Placebo subcutaneous | Inmunotek S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 12/23 | 04/24 | | |
NCT06154304: BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma |
|
|
| Not yet recruiting | 3 | 120 | US | Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Albuterol Test Product, Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Albuterol Reference Product, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo | Cipla Ltd. | Bronchial Asthma | 08/24 | 09/24 | | |
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma |
|
|
| Recruiting | 3 | 64 | RoW | Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI | AstraZeneca | Asthma, Exercise-Induced | 07/24 | 07/24 | | |
GenARA, NCT03015610: Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma |
|
|
| Completed | 3 | 41 | US | commercially available lansoprazole, once daily, matched placebo | Jason Lang, M.D., M.P.H., Thrasher Research Fund, Nemours Children's Clinic | Asthma, Gastroesophageal Reflux | 01/24 | 01/24 | | |
| Recruiting | 3 | 98 | Europe | Fish oil, Active arm, Placebo, Control arm | Norfolk and Norwich University Hospitals NHS Foundation Trust, University of East Anglia | Asthma | 08/24 | 08/24 | | |
| Recruiting | 3 | 150 | Europe | 10,000 MM09, 30,000 MM09, Placebo subcutaneous | Inmunotek S.L., BioClever 2005 S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 01/24 | 12/25 | | |
